<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01536223</url>
  </required_header>
  <id_info>
    <org_study_id>ZhejiangCH13</org_study_id>
    <nct_id>NCT01536223</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma</brief_title>
  <acronym>ESNCCT</acronym>
  <official_title>Cisplatin and 5-fluorouracil(PF) or Docetaxel,Cisplatin and 5-fluorouracil (TPF) Neoadjuvant Chemotherapy With Chemoradiation Therapy for Locally Advanced Nasopharyngeal Carcinoma--A Randomised Prospective Multicenter Phase 3 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Provincial Peopleâ€™s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Locally advanced nasopharyngeal carcinoma patients(UICC7th stageIII to IVb) will receive
      either cisplatin plus 5-fluorouracil (PF) or docetaxel plus cisplatin and 5-fluorouracil(TPF)
      neoadjuvant chemotherapy with concurrent chemoradiation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For locally advanced nasopharyngeal carcinoma patients(UICC7th stageIII to IVb),the
      investigators randomised assign to either 3 cycles of cisplatin plus 5-fluorouracil plus (PF)
      or 3 cycles of docetaxel plus cisplatin and 5-fluorouracil(TPF) neoadjuvant chemotherapy. 21
      days a cycle.

      After the neoadjuvant chemotherapy ,the patients will receive the intensity modulated
      radiotherapy(IMRT) with 2 cycles of concurrent chemotherapy of cisplatin 80mg/m2.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year progress free survival(PFS)</measure>
    <time_frame>3 years after the inception assignment</time_frame>
    <description>PFS means assignment to the date of any local or distant progress of the disease using Kaplan-Meier calculate the progress free survival rates,and find out is there significant difference between these two groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival(OS)</measure>
    <time_frame>2 years ,3 years and 5 years after the inception of the assignment</time_frame>
    <description>the overall survival denote to assignment to date of death from any cause. Using Kaplan-Meier to calculate the 2-year ,3-year,5-year overall survival rate,and find is there any significant difference between these two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>participants will be followed for the duration of hospital stay,an expected average of 100 days and every 3 months thereafter for 5 years</time_frame>
    <description>observe and record the toxicity profile(including but not limit to mucositis,liver and kidney function,et al.)according NCI-CTCAE(3rd edition) during the neoadjuvant chemotherapy ,chemoradiation and follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local control rate (LCR)</measure>
    <time_frame>1 year ,2 years,3 years and 5 years after the inception of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Chemoradiation</condition>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>PF group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the group of participants who undergoing cisplatin and 5-fluorouracil(PF)neoadjuvant chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPF group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TPF(docetaxel , cisplatin and 5-fluorouracil)neoadjuvant chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF (cisplatin and 5-fluorouracil) group</intervention_name>
    <description>the group the patients using PF(cisplatin and 5-fluorouracil )neoadjuvant chemotherapy 3 cycles of neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 100mg/m2 and 5-fluorouracil 4000mg/m2 civ 120 hours And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2.</description>
    <arm_group_label>PF group</arm_group_label>
    <other_name>Active Comparator group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPF (docetaxel plus cisplatin and 5-fluorouracil) group</intervention_name>
    <description>3 cycles of TPF neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2,cisplatin75mg/m2 and 5-fluorouracil 2400mg/m2 civ 96 hours .
And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2.</description>
    <arm_group_label>TPF group</arm_group_label>
    <other_name>Experiment group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with newly histologically confirmed non-keratinizing carcinoma.

          2. Tumor staged as N2-3 or T3-4N1(according to the 7th AJCC staging system)

          3. No evidence of distant metastasis(M0)

          4. Performance status:KPS&gt;70

          5. With normal liver function test(ALT, AST&lt;1.5ULN)

          6. Renal:creatinine clearance &gt;60ml/min

          7. Without hematopathy,marrow:WBC&gt;4*109/L, HGB&gt;80G/L, and PLT&gt;100*109/L.

          8. With controled blood glucose for diabetes patients

          9. Written informed consent

        Exclusion Criteria:

          1. WHO type I squamous cell carcinoma or adenocarcinoma

          2. Age&gt;70 or &lt;18

          3. With a history of renal disease

          4. Prior malignancy (except adequately treated carcinoma in-situ of the cervix or
             basal/squamous cell carcinoma of the skin0

          5. Previous chemotherapy or radiotherapy(except non-melanomatous skin cancers outside the
             intended RT treatment volume)

          6. Patient is pregnant or lactating .

          7. Peripheral neuropathy

          8. Emotional disturbance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaozhong Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaozhong Chen, MD</last_name>
    <phone>86-571-88122098</phone>
    <email>cxzfyun@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Weifeng Qin, MD</last_name>
    <phone>86-571-88122092</phone>
    <email>qinweifeng@yahoo.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaozhong Chen, MD</last_name>
      <phone>86-571-88122098</phone>
      <email>cxzfyun@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Weifeng Qin, MD</last_name>
      <phone>86-571-88122091</phone>
      <email>qinweifeng@yahoo.com.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Xiaozhong Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2012</study_first_submitted>
  <study_first_submitted_qc>February 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2012</study_first_posted>
  <last_update_submitted>March 3, 2013</last_update_submitted>
  <last_update_submitted_qc>March 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nasopharyngeal Carcinoma (NPC)</keyword>
  <keyword>cisplatin and 5-fluorouracil (PF)</keyword>
  <keyword>docetaxel,cisplatin and 5-fluorouracil(TPF)</keyword>
  <keyword>Neoadjuvant Chemotherapy</keyword>
  <keyword>intensity modulated radiotherapy(IMRT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

